A risk-based payment model works to help healthcare providers offer better and more efficient care. Often termed as risk-based payer contracts, this model demands a certain fee from patients that goes to the provider.
Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed
with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year.
It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S.
government's Medicare plan for people age 65 and over, potential side effects and cost.
One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000
per year.
"Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a
massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer.
Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced
the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain
swelling and brain bleeding.
Are you tired of logging onto various payer websites or waiting on the phone to obtain patient insurance eligibility and benefits information? Are you happy with your current solution? Are you using State of the Art technology? Don't waste precious time and money processing patient paperwork only to have your claims denied.